ArticlePeerJ2026
Exploring the frequency of anemia in patients with Axial Spondyloarthritis: associations with inflammatory markers and response to Anti-Tumor Necrosis Factor (TNF)-α therapy.
Article in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Despite the well-established link between systemic inflammation and anemia in rheumatic diseases, the relationship between specific inflammatory markers and both anemia and therapeutic response in axial spondyloarthritis (axSpA) remains unclear. This study aimed to determine the frequency of anemia in patients with axSpA, assess its association with specific inflammatory markers such as the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII) and evaluate the impact of anti-tumor necrosis factor (TNF)-α therapy on these parameters. Methods: This study included 102 patients with axSpA. Patient characteristics and laboratory parameters including C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), hemoglobin (Hb), hematocrit (Hct) and mean corpuscular volume (MCV), and values of NLR, PLR and SII were evaluated at baseline and after 12 months of continuous anti-TNF-α therapy. Results: Anemia frequency dropped from 33.3% to 16.7% after one year of anti-TNF-α therapy. It was more common in females than males ( Conclusion: Anemia is a common comorbidity in axSpA and appears to be closely linked to systemic inflammation. Anti-TNF-α therapy was associated with significant improvements in Hb levels and inflammatory markers over one year. These findings support the value of simple hematologic indices to monitor inflammatory burden and treatment response in axSpA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.